1205540-16-4

Basic information

• Product Name: N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide
• Synonyms: N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide
• CAS NO: 1205540-16-4
• Molecular Weight: 528.331
• Mol File: 1205540-16-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide(1205540-16-4)
• EPA Substance Registry System: N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide(1205540-16-4)

Safety Data

• Hazardous Substances Data: 1205540-16-4(Hazardous Substances Data)

Upstream product

• 350-03-8 methyl-3-pyridylketone 
• 917392-54-2 methyl 4-methyl-3 -[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate 
• 54962-75-3 [3-bromo-5-(trifluoromethyl)phenyl]amine 
• 55314-16-4 3-(N,N-dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one 
• 66521-66-2 4-pyridin-3-ylpyrimidin-2-ylamine 
• 641569-95-1 C₁₁H₁₅N₃O₂ 
• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 641569-97-3 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester 
• 641569-96-2 3-guanidino-4-methylbenzoic acid ethyl ester nitrate 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 2458-12-0 3-amino-p-toluic acid 
• 1205540-17-5 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]benzoyl chloride 

Downstream Products

• 641571-10-0 nilotinib 

Relevant articles and documents

Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors

A series of pyridin-3-yl pyrimidines was synthesized and evaluated for their Bcr-Abl inhibitory and anticancer activity. The preliminary results indicated that some compounds were promising anticancer agents. Compounds A2, A8, and A9 exhibited potent Bcr-Abl inhibitory activity, suggesting that aniline containing halogen substituents might be important for biological activity. Molecular docking was carried out to investigate the binding mode of them with Bcr-Abl. Details of synthesis and SAR studies of these compounds are described. A series of phenylaminopyrimidines was designed and synthesized as potent Bcr-Abl inhibitors. The screening of these rationally designed compounds for antitumor activity had identified three candidate leads which could be further optimized to improve the anticancer activities.

Nilotinib intermediates and preparation thereof

Nilotinib?3HCl and its crystalline forms are described, and processes for the preparation of the same.